Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

This publication has 11 references indexed in Scilit:

• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
  The Lancet, 2019
• Insights into the management of older patients with multiple myeloma.
  2019
• The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
  Clinical Cancer Research, 2019
• CD38 antibodies in multiple myeloma: back to the future
  Blood, 2018
• Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design
  Future Oncology, 2017
• Multiple myeloma in the very elderly patient: challenges and solutions
  Clinical Interventions in Aging, 2015
• RETRACTED ARTICLE: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
  Leukemia, 2015
• SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
  Clinical Cancer Research, 2014
• Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
  Haematologica, 2013
• Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era
  European Journal of Haematology, 2012